What Is Retatrutide? Trial Data and FDA Status in 2026
Quick answer: Retatrutide (LY3437943) is an investigational, once-weekly injectable from Eli Lilly that activates three hormone receptors at once — GIP, GLP-1, and…
Read article →LEARN
Articles
Retatrutide vs Tirzepatide: What the Trial Data Actually Shows
Quick answer: Retatrutide vs tirzepatide comes down to one structural difference — tirzepatide activates two hormone receptors, retatrutide activates three. In separate Phase…
Read article →Retatrutide for Sale: How to Get It and Where It’s Available in 2026
Quick answer: No pharmacy sells retatrutide, at any price, in any country. Every listing advertising retatrutide for sale is a research-chemical vendor, not…
Read article →Retatrutide Side Effects: What the Phase 3 Trials Actually Found
Quick answer: The most common retatrutide side effects are gastrointestinal — nausea affected 42.4% of participants at the 12 mg dose in TRIUMPH-1,…
Read article →Retatrutide Results: What the Phase 3 Trials Actually Delivered
Quick answer: In TRIUMPH-1, participants on the 12 mg dose lost an average of 70.3 lbs — 28.3% of body weight — over…
Read article →Retatrutide Dosage and Dosing : What the Clinical Trials Actually Used
Quick answer: There is no approved retatrutide dosage, because retatrutide is not an approved drug. In the Phase 3 TRIUMPH trials, the retatrutide…
Read article →Retatrutide Cost: What It Will Likely Price At
Quick answer: Retatrutide has no cost, because it is not an approved drug and cannot be bought or prescribed. Comparable medications in 2026…
Read article →Retatrutide Peptide: Is It the Same Molecule as the Drug in Trials?
Quick answer: Retatrutide is a 39-amino-acid peptide with three non-standard residues and a fatty diacid chain attached at a specific lysine. Whether a…
Read article →Retatrutide UK: Availability, Legal Status and Timeline
Quick answer: Retatrutide is not available in the UK. It has no MHRA marketing authorisation, so no doctor can prescribe it — not…
Read article →Retatrutide FDA Approval Status
Status as of 7 August 2026: not approved. Retatrutide has no FDA approval for any indication. Eli Lilly announced on 23 July 2026…
Read article →